The approval is for adults who have experienced disease progression on or after platinum-based chemotherapy.
EGFR+ Non-Small Cell Lung Cancer
Advertisement
The study investigated HER3-DXd in patients with advanced EGFRm NSCLC after progression during treatment with an EGFR TKI.
The approval is for adults who have received prior EGFR-directed therapy and platinum-based chemotherapy.
Dr. Califano discusses what the study showed about baseline mechanisms of resistance to osimertinib and associated outcomes.
Local therapy is recommended by NCCN guidelines, but how it is used in oligoprogressive disease is not well described.
Helena Yu, MD, discusses research updates from REZILIENT1 that were presented at ASCO 2025.
The study compared treatment with neoadjuvant osimertinib with or without chemotherapy versus chemotherapy alone.
Jennifer Carlisle, MD, discusses amivantamab, and the multidimensional impact of toxicity management at ASCO 2025.
Dr. Spira shares key data from cohort C of CHRYSALIS-2 that was presented at the European Lung Cancer Congress 2025.
Dr. Liu discusses key data and updates in EGFR-positive NSCLC from the European Lung Cancer Congress.
Nicolas Girard, MD, PhD, discusses data on subcutaneous amivantamab in patients with advanced NSCLC.
Expert Interviews
Advertisement